Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal Hepatitis B Vaccine with Imiquimod in Renal Failure
NCT02621112Phase 3Completed
- Sponsor
- The University of Hong Kong
- Start
- Jan 2016
- Primary completion
- Dec 2018
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Hepatitis B vaccine and imiquimod in hepatitis B (HBV) (3 arms), sponsored by The University of Hong Kong. Primary endpoint: Seroprotection rate to HBV at 12 months. Started Jan 2016; status: completed.
02
Drugs
Hepatitis B vaccineimiquimod
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02621112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621112.